New drug trial offers hope for debilitating muscle disease

This early-stage clinical trial is testing whether an experimental drug called ripertamab is safe and effective for treating generalized myasthenia gravis, a chronic autoimmune disease that causes muscle weakness. The study will involve 20 adults who will receive either ripertamab or a placebo (inactive substance) through a single IV infusion, then be monitored for 13 weeks to see if their symptoms improve and to check for side effects. Researchers will track participants' daily symptoms and measure whether they need less rescue therapy while on the treatment.